NORWOOD, Massachusetts., May 8, 2023 /PRNewswire/ — Groundbreaking research conducted by a team of leading researchers in Domestic Bioscience (EBS) and University of Florida reveals significant discoveries that will change the way we understand amino acid combinations and represents the next generation of oral rehydration solutions (ORS). Sadasivan VidyasagarMBBS, PhD and Associate Professor in the Department of Radiation Oncology, University of Florida, led the team in this study. Dr. Vidyasagar is also the founder of Entrinsic Bioscience and chairman of the Entrinsic Scientific Advisory Board. The report, titled “Selected Amino Acids (AA-ORS) Improve Electrolyte and Fluid Absorption in a Rodent Model of Diarrhea,” was presented yesterday by Astrid GrochetPh.D, University of Floridaat a plenary session during Digestive Disease Week (May 6-9) in Chicago.
The study demonstrated that Entrinsic’s AA-ORS was superior to WHO-ORS in increasing electrolyte and fluid absorption in the presence of cholera toxin, reducing epithelial anion channel activity, and improving intestinal barrier function. This improved ORS formulation will now be tested in clinical trials for validation as a new treatment option for patients with infectious diarrhea.
These findings are expected to have a significant impact on the field as they represent a breakthrough in rehydration technology. A precise, proprietary blend of amino acids was used to provide active transport of electrolytes and water into the blood stream without glucose and demonstrated superior results over glucose-based WHO-ORS.
“We are excited to announce the results of our latest research and share statistically significant data to demonstrate the superiority of this ORS in the complete absence of sugar,” says Dr. Vidyasagar. “The findings not only confirm the effectiveness of this amino acid product, but also represent the next generation of oral hydration solutions and will inform our future development and innovation.”
Acute diarrheal infection causes almost 700 million illnesses worldwide each year. Infectious diarrhea leads to massive fluid loss, severe dehydration, and is a leading cause of childhood mortality and morbidity worldwide. In 1962, WHO introduced the first glucose-based ORS formula, saving many millions of lives worldwide. The standard of care, especially for home presentations, included the use of sugar (glucose)-based oral rehydration solutions to increase replacement of water and salt losses. But there are concerns about glucose’s potential to impair intestinal secretion, thereby delaying recovery.
In 2004, the WHO updated its ORS formula to improve tolerability by reducing glucose and electrolyte levels. Entrinsic AA-ORS will now be tested in clinical validation trials in patients with infectious diarrhea.
“This study builds on Entrinsic Bioscience’s extensive research demonstrating the potential of amino acids to be an important advance over sugar in oral rehydration solutions,” says Charles Mohs, president of Entrinsic Consumer Healthcare. “This preclinical study demonstrates the superiority of intrinsic amino acid-based ORS in increasing electrolyte and fluid absorption and improving intestinal barrier function.”
Dr. Vidyasagar and Entrinsic experts will be available at booth #5217 in the South Building to answer any questions about the study. They will also discuss the launch of Enterade® IBS-D, which uses a proprietary combination of Entrinsic amino acids in its formula. Enterade IBS-D is a medical food formulated for the dietary management of gastrointestinal symptoms associated with IBS-D.
About Intrinsic Bioscience
Entrinsic Bioscience (EBS) is a pioneering life sciences company that combines its proprietary platform and discovery engine to deliver next-generation proprietary therapeutic compounds, functional ingredients and product innovations designed to deliver multiple health and wellness benefits to users. Through proprietary biomapping and electrophysiology techniques, the EBS platform harnesses the body’s natural processes to restore, protect and improve health and well-being.
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Co-sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society for Surgery of the Digestive Tract (SSAT), DDW is an in-person and online meeting from May 6-9, 2023. The meeting showcases more than 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine, and technology. More information can be found at www.ddw.org.
Media contact: Angie Oberholzer, [email protected]484.241.6926
SOURCE Entrinsic Bioscience